english.prescrire.org > Spotlight > 100 most recent > In the April issue of Prescrire International: Dupilumab (Dupixent°) in severe atopic eczema from 6 years of age

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the April issue of Prescrire International: Dupilumab (Dupixent°) in severe atopic eczema from 6 years of age

FREE DOWNLOAD Dupilumab is an immunosuppressant monoclonal antibody which was already authorised in the European Union for use in adults and adolescents with troublesome atopic eczema. How do Prescrire's editors rate this drug in younger children?
Full text available for free download.

Prescrire's rating

  •  JUDGEMENT RESERVED  When an immunosuppressant is being considered for children with atopic eczema, dupilumab shows some efficacy, as in adults and adolescents, based on its evaluation data. However, given the usually spontaneous improvement in this condition before adolescence, and the many unknowns regarding the long-term adverse effects of dupilumab in children, its harm-benefit balance remains uncertain. As of late 2021, in view of the potential risks to children treated with this drug, it should be reserved for use in the supervised setting of clinical trials.

©Prescrire 1 April 2022

Source: "Dupilumab (Dupixent°) in severe atopic eczema from 6 years of age" Prescrire International 2022; 31 (236): 92. Free.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


Prescrire's rating:

Prescrire's rating
 JUDGEMENT RESERVED 


See also:

"Prescrire's ratings for new
drugs and new indications"
(February 2022)
Free


Read more:

All the subjects in
Prescrire's Spotlight
Free >